Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer

Basit Öğe Kaydı
dc.authoridKaya, Ertugrul/0000-0003-0081-682X|Yaykasli, Kursat/0000-0001-7550-6370|yilmaz, nesibe/0000-0002-5527-8507;
dc.contributor.authorYaykasli, Kursat Oguz
dc.contributor.authorKayikci, Muhammet Ali
dc.contributor.authorYamak, Nesibe
dc.contributor.authorSoguktas, Hatice
dc.contributor.authorDuzenli, Selma
dc.contributor.authorArslan, Ali Osman
dc.contributor.authorMetin, Ahmet
dc.date.accessioned2025-10-24T18:09:51Z
dc.date.available2025-10-24T18:09:51Z
dc.date.issued2014
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractAim: Prostate cancer is the most commonly diagnosed malignancy and the second most common cause of cancer deaths in the Western male population. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) modulate the remodeling of the extracellular matrix (ECM). The imbalance between MMPs and TIMPs may lead to an emergence of pathological processes such as cancer. In this study, the association between TIMP-2 (-418 G/C) and MMP-2 (-1306 C/T) polymorphisms and prostate cancer in the Turkish population was investigated. Materials and methods: Sixty-one prostate cancer patients and 46 healthy subjects were included in the study. DNA was isolated from 2 mL of peripheral blood taken from subjects, and genotypes were analyzed by the polymerase chain reaction-restriction fragment length polymorphism method. Results: The TIMP-2 418 (GC) genotype was found in 15 cases (32.6%) in the control group and in 9 cases (14.8%) in the patients group, and statistical significance was determined (P = 0.037, OR = 0.346). The MMP-2 1306 (CT) genotype was found 2.17 times more in the patient group than in the control group (P = 0.149, OR = 2.17). Conclusion: Our results show that the TIMP-2 418 (GC) genotype had a putative protective effect against prostate cancer.
dc.description.sponsorshipDuzce University Research Fund [2012.04.02.107]
dc.description.sponsorshipThis project was supported by the Duzce University Research Fund, Project Number 2012.04.02.107.
dc.identifier.doi10.3906/sag-1305-63
dc.identifier.endpage843
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue5
dc.identifier.pmid25539555
dc.identifier.scopus2-s2.0-84905659763
dc.identifier.scopusqualityQ1
dc.identifier.startpage839
dc.identifier.trdizinid213183
dc.identifier.urihttps://doi.org/10.3906/sag-1305-63
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/213183
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3865
dc.identifier.volume44
dc.identifier.wosWOS:000343068800021
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal Of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectMatrix metalloproteinases; prostate cancer; polymorphism; tissue inhibitors of metalloproteinases
dc.titlePolymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu